Insider trading

Period: 120 months Stock: GNLX Type of trade: Sold × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

112 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

112 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

112 decisions over 120 months Remove this filter
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

112 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
112 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
112 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

112 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
31 Aug 2026
Zindrick Thomas President and CEO
Sold at will
$91.90K 34,463 at 2.67
2.7%
Not planned
31 Aug 2026
Cappello Joseph Chief Technical Officer
Sold at will
$28.11K 10,257 at 2.74
3.1%
Not planned
31 Aug 2026
Yu Yong Chief Scientific Officer
Sold at will
$26.66K 9,683 at 2.75
3.6%
Not planned
4 Aug 2026
Zindrick Thomas President and CEO
Sold at will
$8.91K 3,023 at 2.95
0.2%
Not planned
4 Aug 2026
Cappello Joseph Chief Technical Officer
Sold at will
$1.92K 653 at 2.95
0.2%
Not planned
4 Aug 2026
Yu Yong Chief Scientific Officer
Sold at will
$1.92K 653 at 2.94
0.2%
Not planned
1 Jul 2026
Smither John W Director
Sold at will
$34.90K 12,000 at 2.91
11.6%
Not planned
3 Jun 2026
Smalling Ralph Head of Regulatory
Sold at will
$562.56 192 at 2.93
0.3%
Not planned
1 Jun 2026
Thomas John Director
Sold on a plan
$29.80K 10,000 at 2.98
2.1%
Planned (10b5-1)
11 May 2026
Zindrick Thomas President and CEO
Sold at will
$8.23K 2,798 at 2.94
0.5%
Not planned
11 May 2026
Cappello Joseph Chief Technical Officer
Sold at will
$1.80K 605 at 2.97
0.4%
Not planned
11 May 2026
Yu Yong Chief Scientific Officer
Sold at will
$1.80K 605 at 2.97
0.4%
Not planned
11 May 2026
Smalling Ralph Head of Regulatory
Sold at will
$804.49 270 at 2.98
0.4%
Not planned
25 Mar 2026
Smalling Ralph Head of Regulatory
Sold at will
$602.40 240 at 2.51
0.4%
Not planned
24 Mar 2026
Zindrick Thomas President and CEO
Sold at will
$8.67K 3,582 at 2.42
0.7%
Not planned
24 Mar 2026
Yu Yong SVP, Clinical Development
Sold at will
$2.19K 906 at 2.42
0.6%
Not planned
24 Mar 2026
Cappello Joseph Chief Technical Officer
Sold at will
$2.19K 906 at 2.42
0.6%
Not planned
24 Mar 2026
Smalling Ralph Head of Regulatory
Sold at will
$834.90 345 at 2.42
0.5%
Not planned
2 Mar 2026
Thomas John Director
Sold on a plan
$28.96K 10,000 at 2.90
2.0%
Planned (10b5-1)
5 Dec 2025
Smalling Ralph Head of Regulatory
Sold at will
$773.85 165 at 4.69
0.2%
Not planned
1 Dec 2025
Thomas John Director
Sold on a plan
$50.01K 10,000 at 5.00
2.0%
Planned (10b5-1)
17 Nov 2025
Zindrick Thomas President and CEO
Sold at will
$24.21K 4,509 at 5.37
0.8%
Not planned
17 Nov 2025
Cappello Joseph Chief Technical Officer
Sold at will
$5.22K 973 at 5.37
0.6%
Not planned
17 Nov 2025
Yu Yong SVP, Clinical Development
Sold at will
$5.22K 973 at 5.37
0.7%
Not planned
17 Nov 2025
Smalling Ralph Head of Regulatory
Sold at will
$1.84K 343 at 5.37
0.5%
Not planned
3 Sep 2025
Smalling Ralph Head of Regulatory
Sold at will
$1.95K 580 at 3.36
0.8%
Not planned
21 Aug 2025
Zindrick Thomas President and CEO
Sold at will
$42.16K 12,673 at 3.33
2.3%
Not planned
21 Aug 2025
Yu Yong SVP, Clinical Development
Sold at will
$10.81K 3,219 at 3.36
2.1%
Not planned
21 Aug 2025
Cappello Joseph Chief Technical Officer
Sold at will 2×
$9.14K 2,733 at 3.34
1.7%
Not planned
21 Aug 2025
Smalling Ralph Head of Regulatory
Sold at will
$4.18K 1,244 at 3.36
1.8%
Not planned
12 May 2025
Zindrick Thomas President and CEO
Sold at will
$31.43K 10,764 at 2.92
5.3%
Not planned
12 May 2025
Yu Yong VP, Clinical Trial Operations
Sold at will
$16.29K 5,579 at 2.92
10.5%
Not planned
12 May 2025
Cappello Joseph VP, Pharmaceutical Development
Sold at will
$13.83K 4,737 at 2.92
8.3%
Not planned
12 May 2025
Ryder Sean General Counsel
Sold at will
$13.07K 4,475 at 2.92
8.6%
Not planned
12 May 2025
Smalling Ralph Head of Regulatory
Sold at will
$3.68K 1,259 at 2.92
3.5%
Not planned
30 Dec 2024
Tyree James L Director
Sold at will
$8.51K 3,460 at 2.46
7.0%
Not planned
16 Dec 2024
Zindrick Thomas President and CEO
Sold at will
$33.50K 14,315 at 2.34
27.7%
Not planned
16 Dec 2024
Cappello Joseph VP, Pharmaceutical Development
Sold at will
$14.74K 6,300 at 2.34
30.1%
Not planned
16 Dec 2024
Smalling Ralph Head of Regulatory
Sold at will
$5.87K 2,510 at 2.34
13.3%
Not planned
16 Dec 2024
Zak Lourie S. Chief Financial Officer
Sold at will
$4.92K 2,103 at 2.34
4.9%
Not planned
13 Sep 2024
Szalay Aladar 10% owner · indirect
Sold at will
$84.95K 33,080 at 2.57
5.2%
Not planned
12 Sep 2024
Szalay Aladar 10% owner · indirect
Sold at will
$86.73K 31,777 at 2.73
4.8%
Not planned
11 Sep 2024
Szalay Aladar 10% owner · indirect
Sold at will
$82.23K 31,376 at 2.62
4.5%
Not planned
11 Sep 2024
Tyree James L Director
Sold on a plan
$4.50K 1,730 at 2.60
3.5%
Planned (10b5-1)
10 Sep 2024
Szalay Aladar 10% owner · indirect
Sold at will
$51.18K 20,384 at 2.51
2.8%
Not planned
9 Sep 2024
Szalay Aladar 10% owner · indirect
Sold at will
$63.20K 23,383 at 2.70
3.2%
Not planned
3 Sep 2024
Szalay Aladar 10% owner · indirect
Sold at will
$89.61K 42,818 at 2.09
5.5%
Not planned
30 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$309.85K 142,589 at 2.17
15.4%
Not planned
29 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$211.96K 107,045 at 1.98
10.4%
Not planned
28 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$32.60K 15,918 at 2.05
1.5%
Not planned
Showing 1–50 of 112. Page 1 of 3 Older →